Friday, September 4, 2026

Nautilus Stock Sails High With 30% Surge In 5 Days - Is It Time To Buy?

ViaNews Editorial Team

December 4, 2023

Nautilus Stock Sails High With 30% Surge In 5 Days - Is It Time To Buy?

(VIANEWS) - Nautilus Shares Rise 30.16% in Five Sessions and Recoup From Recent Losses Shares of fitness equipment manufacturer Nautilus (NYSE ticker symbol NLS) experienced an extraordinary surge over the last five sessions, rising 30.16% from EUR0.63 at 30.16 to EUR0.82 by 18:05 EST Monday afternoon after three consecutive declines. Nautilus shares remain 73.73% below their 52-week high of EUR2.17; their last closing price was EUR0.57. Overall market performance on the NYSE has been positive, with its index rising 1.09% to EUR16,263.75. This rise comes after three consecutive sessions of gains. Investors should closely track market and company trends in order to make an informed decision regarding their investments in Nautilus.

About Nautilus

Nautilus, Inc. provides fitness solutions worldwide by designing, developing, sourcing and marketing cardio and strength fitness products as well as related accessories to consumers in various regions worldwide. Nautilus Inc operates through two segments: Direct and Retail. Their direct business offers products under the Nautilus, Bowflex and Schwinn brands as well as digital fitness platform JRNY; while licensing of brands and intellectual properties. Nautilus Inc. markets its products via television advertisements, social media, websites, catalogs and retail companies such as sporting goods stores, online-only retailers, electronics stores, furniture stores, large format warehouse stores and specialty bike dealers. Established in 1986 in Vancouver Washington; headquarters are currently in Vancouver Washington

Yearly Analysis

According to available data, Nautilus stock is currently trading at EUR0.82, significantly below its 52-week high of EUR2.17 but above its low of EUR0.64. This indicates significant fluctuations over the past year for Nautilus' stock. As for sales growth, Nautilus anticipates negative 2.8% this year but anticipates rebounding to positive 9% growth next year due to anticipated increases in product demand. Nautilus currently boasts an EBITDA ratio of 0.18, signifying positive earnings before interest, taxes, depreciation and amortization. This suggests that its operations are producing profits while its financial performance remains strong. Overall, Nautilus appears to be an attractive investment choice with potential for strong sales and earnings growth in 2018. Investors should continue monitoring the company's performance and the broader economic environment to make informed investment decisions.

Technical Analysis

Nautilus stock is trading above its 50-day moving average of EUR0.75, yet significantly below its 200-day moving average of EUR1.14. This indicates a downward trend, yet potential for rebound in the longer term. Furthermore, Nautilus' volume stands at 269,6889 which is 32.65% greater than average volumes 203,301 suggesting increased trading activity. In recent weeks, months, and quarters, volatility of this stock was relatively low with average intraday variation between -0.82%, -2.21%, and 3.81%; however, its highest amplitude of average volatility being 0.83% in each case (0.83% for week, month and quarter respectively), suggesting it can fluctuate considerably over time. According to the stochastic oscillator, Nautilus stock is currently considered overbought (>=80), suggesting it could experience short-term correction. Investors should carefully evaluate other factors like financial performance and industry trends when making any investment decisions.

Quarter Analysis

Investment Outlook: Based on the available data, Nautilus' current quarter sales growth stands at negative 20.2% while growth estimates for the upcoming and ongoing quarters stand at 36.6% and 82.9% respectively - meaning they should experience significant sales and revenue increases in subsequent quarters. Nautilus' year-on-year quarterly revenue growth stands at 61.78% with total revenues reaching 735.32M over twelve trailing months - suggesting strong and sustainable revenue expansion potential going forward. Overall, investors may wish to consider Nautilus as an investment opportunity given their anticipated sales and revenue growth; however, additional research and analysis must be completed prior to making any definitive decisions regarding investing.

Equity Analysis

Nautilus, Inc. appears to offer an attractive dividend yield of 4.09% and may make an attractive choice for income-seeking investors. It should be noted, however, that its trailing twelve month EPS (-1.63) suggests it may not yet be profitable and its return on equity (75.4%) suggests its shareholder equity may be being utilized effectively to generate profits - an indicator which investors should carefully consider alongside other financial and industry data before making investment decisions.

More news about Nautilus (NLS).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com